Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience.
neutrophil‐to‐lymphocyte ratio
osteosarcoma
pediatric
prognostic factor
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
28 Apr 2024
28 Apr 2024
Historique:
revised:
18
03
2024
received:
24
04
2022
accepted:
04
04
2024
medline:
29
4
2024
pubmed:
29
4
2024
entrez:
29
4
2024
Statut:
aheadofprint
Résumé
Previous studies have shown that neutrophil-to-lymphocyte (NLR) ratio at diagnosis and early lymphocytes recovery on doxorubicin-based chemotherapy, may impact the outcome in patients with osteosarcoma (OST). This study aimed to evaluate the prognostic value of hemogram parameters in patients with OST treated with high-dose methotrexate and etoposide/ifosfamide (M-EI) chemotherapy. We retrospectively analyzed the prognostic value of various hemogram parameters at diagnosis and during therapy in a large consecutive cohort of patients with OST included in the French OS2006 trial and treated with M-EI chemotherapy. A total of 164 patients were analyzed. The median age was 14.7 years (interquartile range [IQR]: 11.7-17). Median follow-up was 5.6 years (IQR: 3.3-7.7 years). Three-year event-free survival (EFS) and overall survival (OS) were 71.5% (95% confidence interval [CI]: 64%-78%) and 86.4% (95% CI: 80%-91%), respectively. In univariate analysis, blood count parameters at diagnosis and early lymphocyte recovery at Day 14 were not found prognostic of survival outcomes. By contrast, an increase of NLR ratio at Day 1 of the first EI chemotherapy (NLR-W4) was associated with reduced OS in univariate (p = .0044) and multivariate analysis (hazards ratio [HR] = 1.3, 95% CI: 1.1-1.5; p = .002), although not with EFS. After adjustment on histological response and metastatic status, an increase of the ratio NLR-W4 of 1 was associated with an increased risk of death of 30%. We identified NLR-W4 as a potential early biomarker for survival in patients with OST treated with M-EI chemotherapy. Further studies are required to confirm the prognostic value of NLR and better identify immune mechanisms involved in disease surveillance.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have shown that neutrophil-to-lymphocyte (NLR) ratio at diagnosis and early lymphocytes recovery on doxorubicin-based chemotherapy, may impact the outcome in patients with osteosarcoma (OST). This study aimed to evaluate the prognostic value of hemogram parameters in patients with OST treated with high-dose methotrexate and etoposide/ifosfamide (M-EI) chemotherapy.
MATERIALS AND METHODS
METHODS
We retrospectively analyzed the prognostic value of various hemogram parameters at diagnosis and during therapy in a large consecutive cohort of patients with OST included in the French OS2006 trial and treated with M-EI chemotherapy.
RESULTS
RESULTS
A total of 164 patients were analyzed. The median age was 14.7 years (interquartile range [IQR]: 11.7-17). Median follow-up was 5.6 years (IQR: 3.3-7.7 years). Three-year event-free survival (EFS) and overall survival (OS) were 71.5% (95% confidence interval [CI]: 64%-78%) and 86.4% (95% CI: 80%-91%), respectively. In univariate analysis, blood count parameters at diagnosis and early lymphocyte recovery at Day 14 were not found prognostic of survival outcomes. By contrast, an increase of NLR ratio at Day 1 of the first EI chemotherapy (NLR-W4) was associated with reduced OS in univariate (p = .0044) and multivariate analysis (hazards ratio [HR] = 1.3, 95% CI: 1.1-1.5; p = .002), although not with EFS. After adjustment on histological response and metastatic status, an increase of the ratio NLR-W4 of 1 was associated with an increased risk of death of 30%.
CONCLUSIONS
CONCLUSIONS
We identified NLR-W4 as a potential early biomarker for survival in patients with OST treated with M-EI chemotherapy. Further studies are required to confirm the prognostic value of NLR and better identify immune mechanisms involved in disease surveillance.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31029Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Fritzsching B, Fellenberg J, Moskovszky L, et al. CD8+/FOXP3+‐ratio in osteosarcoma microenvironment separates survivors from non‐survivors: a multicenter validated retrospective study. Oncoimmunology. 2015;4:e990800. doi:10.4161/2162402X.2014.990800
Gomez‐Brouchet A, Illac C, Gilhodes J, et al. CD163‐positive tumor‐associated macrophages and CD8‐positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: an immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial. Oncoimmunology. 2017;6:e1331193. doi:10.1080/2162402X.2017.1331193
Dumars C, Ngyuen J‐M, Gaultier A, et al. Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma. Oncotarget. 2016;7:78343‐78354. doi:10.18632/oncotarget.13055
Vasquez L, León E, Beltran B, Maza I, Oscanoa M, Geronimo J. Pretreatment neutrophil‐to‐lymphocyte ratio and lymphocyte recovery: independent prognostic factors for survival in pediatric sarcomas. J Pediatr Hematol Oncol. 2017;39:538‐546. doi:10.1097/MPH.0000000000000911
Moore C, Eslin D, Levy A, Roberson J, Giusti V, Sutphin R. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr Blood Cancer. 2010;55:1096‐1102. doi:10.1002/pbc.22673
Lee L, Fei L, Pope J, Wagner LM. Early lymphocyte recovery and outcome in osteosarcoma. J Pediatr Hematol Oncol. 2017;39:179‐183. doi:10.1097/MPH.0000000000000717
Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: a meta‐analysis. Clinics. 2015;70:524‐530. doi:10.6061/clinics/2015(07)10
Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil‐to‐lymphocyte ratio in solid tumors: a systematic review and meta‐analysis. J Natl Cancer Inst. 2014;106:dju124. doi:10.1093/jnci/dju124
Kayadibi H, Sertoglu E, Uyanik M, Tapan S. Neutrophil‐lymphocyte ratio is useful for the prognosis of patients with hepatocellular carcinoma. World J Gastroenterol. 2014;20:9631‐9632. doi:10.3748/wjg.v20.i28.9631
Mei Z, Shi L, Wang B, et al. Prognostic role of pretreatment blood neutrophil‐to‐lymphocyte ratio in advanced cancer survivors: a systematic review and meta‐analysis of 66 cohort studies. Cancer Treat Rev. 2017;58:1‐13. doi:10.1016/j.ctrv.2017.05.005
Piperno‐Neumann S, Le Deley M‐C, Rédini F, et al. Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open‐label, phase 3 trial. Lancet Oncol. 2016;17:1070‐1080. doi:10.1016/S1470‐2045(16)30096‐1
Le Deley M‐C, Guinebretière J‐M, Gentet J‐C, et al. SFOP OS94: a randomised trial comparing preoperative high‐dose methotrexate plus doxorubicin to high‐dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752‐761. doi:10.1016/j.ejca.2006.10.023
Casali PG, Bielack S, Abecassis N, et al. Bone sarcomas: ESMO‐PaedCan‐EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2018;29:iv79‐iv95. doi:10.1093/annonc/mdy310
Ameratunga M, Chénard‐Poirier M, Moreno Candilejo I, et al. Neutrophil‐lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD‐1/PD‐L1 inhibitors. Eur J Cancer. 2018;89:56‐63. doi:10.1016/j.ejca.2017.11.012
Gomez‐Brouchet A, Gilhodes J, Acker NV, et al. Characterization of macrophages and osteoclasts in the osteosarcoma tumor microenvironment at diagnosis: new perspective for osteosarcoma treatment? Cancers. 2021;13:423. doi:10.3390/cancers13030423
Liu T, Fang X‐C, Ding Z, Sun Z‐G, Sun L‐M, Wang Y‐L. Pre‐operative lymphocyte‐to‐monocyte ratio as a predictor of overall survival in patients suffering from osteosarcoma. FEBS Open Bio. 2015;5:682‐687. doi:10.1016/j.fob.2015.08.002
Que Y, Qiu H, Li Y, et al. Preoperative platelet‐lymphocyte ratio is superior to neutrophil‐lymphocyte ratio as a prognostic factor for soft‐tissue sarcoma. BMC Cancer. 2015;15:648. doi:10.1186/s12885‐015‐1654‐6
Gaspar N, Occean B‐V, Pacquement H, et al. Results of methotrexate‐etoposide‐ifosfamide based regimen (M‐EI) in osteosarcoma patients included in the French OS2006/Sarcome‐09 study. Eur J Cancer. 2018;88:57‐66. doi:10.1016/j.ejca.2017.09.036
Motomura T, Shirabe K, Mano Y, et al. Neutrophil‐lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment. J Hepatol. 2013;58:58‐64. doi:10.1016/j.jhep.2012.08.017
van Erp AEM, Versleijen‐Jonkers YMH, Hillebrandt‐Roeffen MHS, et al. Expression and clinical association of programmed cell death‐1, programmed death‐ligand‐1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget. 2017;8:71371‐71384. doi:10.18632/oncotarget.19071